TY - JOUR
T1 - Percutaneous extracorporeal arteriovenous carbon dioxide removal improves survival in respiratory distress syndrome
T2 - A prospective randomized outcomes study in adult sheep
AU - Zwischenberger, Joseph B.
AU - Alpard, Scott K.
AU - Tao, Weike
AU - Deyo, Donald J.
AU - Bidani, Akhil
N1 - Funding Information:
Supported in part by Shriners Hospitals for Children (grant No. 8530) and the Constance Marsili Shafer Research Fund.
PY - 2001
Y1 - 2001
N2 - Objective: Arteriovenous carbon dioxide removal (AVCO2R) uses a simple arteriovenous shunt for CO2 removal to minimize barotrauma/volutrauma from mechanical ventilation. We performed a prospective randomized outcomes study of AVCO2R in our new, clinically relevant model of respiratory distress syndrome. Methods: Adult sheep (n = 18) received an LD50 severe smoke inhalation and 40% third-degree burn. When respiratory distress syndrome developed (PaO2/FIO2 < 200 at 40 to 48 hours), animals were randomized to the AVCO2R (n = 9) or sham group (n = 9) for 7 days. Ventilator management protocols mandated reductions in minute ventilation, first tidal volume to peak inspiratory pressure less than 30 cm H2O, then respiratory rate when PaCO2 was less than 40 mm Hg. Pao2 was kept above 60 mm Hg by adjusting FIO2. When FIO2 was 0.21, animals were weaned. Results: The study required 2946 animal-hours of critical care with 696 AVCO2R hours. One died in each group during model development. AVCO2R flow from 820 mL/min to 970 mL/min (11% to 14% cardiac output) removed CO2 at a rate of 92 to 116 mL/min (mean 103 mL/min; 93%-97% of CO2 production). Heart rate, mean arterial pressure, cardiac output, and pulmonary arterial wedge pressure remained relatively constant. Within 48 hours, AVCO2R allowed significant ventilator reductions versus baseline in the following measurements: tidal volume (420 to 270 mL), peak inspiratory pressure (25 to 14 cm H2O), minute ventilation (13 to 5 L/min), respiratory rate (26 to 16 breaths/min), and FIO2 (0.88 to 0.35). Ventilator-free days with AVCO2R were 3.9 versus 0.2 (P < .01) for sham animals, and ventilator-dependent days with AVCO2R were 2.4 versus 6.2 (P < .01) for the 3 sham survivors. All 8 AVCO2R animals and 3 of 8 sham animals survived 7 days after randomization. Conclusions: Percutaneous AVCO2R achieved significant reduction in airway pressures, increased ventilator-free days, decreased ventilator-dependent days, and improved survival in a sheep model of respiratory distress syndrome.
AB - Objective: Arteriovenous carbon dioxide removal (AVCO2R) uses a simple arteriovenous shunt for CO2 removal to minimize barotrauma/volutrauma from mechanical ventilation. We performed a prospective randomized outcomes study of AVCO2R in our new, clinically relevant model of respiratory distress syndrome. Methods: Adult sheep (n = 18) received an LD50 severe smoke inhalation and 40% third-degree burn. When respiratory distress syndrome developed (PaO2/FIO2 < 200 at 40 to 48 hours), animals were randomized to the AVCO2R (n = 9) or sham group (n = 9) for 7 days. Ventilator management protocols mandated reductions in minute ventilation, first tidal volume to peak inspiratory pressure less than 30 cm H2O, then respiratory rate when PaCO2 was less than 40 mm Hg. Pao2 was kept above 60 mm Hg by adjusting FIO2. When FIO2 was 0.21, animals were weaned. Results: The study required 2946 animal-hours of critical care with 696 AVCO2R hours. One died in each group during model development. AVCO2R flow from 820 mL/min to 970 mL/min (11% to 14% cardiac output) removed CO2 at a rate of 92 to 116 mL/min (mean 103 mL/min; 93%-97% of CO2 production). Heart rate, mean arterial pressure, cardiac output, and pulmonary arterial wedge pressure remained relatively constant. Within 48 hours, AVCO2R allowed significant ventilator reductions versus baseline in the following measurements: tidal volume (420 to 270 mL), peak inspiratory pressure (25 to 14 cm H2O), minute ventilation (13 to 5 L/min), respiratory rate (26 to 16 breaths/min), and FIO2 (0.88 to 0.35). Ventilator-free days with AVCO2R were 3.9 versus 0.2 (P < .01) for sham animals, and ventilator-dependent days with AVCO2R were 2.4 versus 6.2 (P < .01) for the 3 sham survivors. All 8 AVCO2R animals and 3 of 8 sham animals survived 7 days after randomization. Conclusions: Percutaneous AVCO2R achieved significant reduction in airway pressures, increased ventilator-free days, decreased ventilator-dependent days, and improved survival in a sheep model of respiratory distress syndrome.
UR - http://www.scopus.com/inward/record.url?scp=0035076052&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035076052&partnerID=8YFLogxK
U2 - 10.1067/mtc.2001.112828
DO - 10.1067/mtc.2001.112828
M3 - Article
C2 - 11241090
AN - SCOPUS:0035076052
SN - 0022-5223
VL - 121
SP - 542
EP - 551
JO - Journal of Thoracic and Cardiovascular Surgery
JF - Journal of Thoracic and Cardiovascular Surgery
IS - 3
ER -